Addition of Clofarabine to TLI/ATG Conditioning: Impact on Immune Reconstitution and Clinical Outcomes

Brett Glotzbecker(Dana-Farber Cancer Institute), David Avigan(Beth Israel Deaconess Medical Center), Vassiliki A. Boussiotis(Beth Israel Deaconess Medical Center), Jon Arnason(Beth Israel Deaconess Medical Center), Robin Joyce(Beth Israel Deaconess Medical Center), Thomas R. Spitzer(Harvard University), Jessica Bonhoff(Beth Israel Deaconess Medical Center), Karen K. Ballen(University of Virginia Health System), Carol Delaney(Beth Israel Deaconess Medical Center), Jacalyn Rosenblatt(Beth Israel Deaconess Medical Center), Caitlin McMahon(Beth Israel Deaconess Medical Center), Jamie Mortellite(Beth Israel Deaconess Medical Center), Katarina Luptakova(Tesaro (United States)), Baldev Vasir(Beth Israel Deaconess Medical Center), Katharine Conway(Beth Israel Deaconess Medical Center), Dimitrios Tzachanis(Dana-Farber Cancer Institute), Y.-B. Chen(Massachusetts General Hospital), Nancy Giallombardo(Beth Israel Deaconess Medical Center), Eyal C. Attar(Memorial Sloan Kettering Cancer Center), Mark A. Stevenson(The University of Melbourne), Dina Stroopinsky(Beth Israel Deaconess Medical Center), Heidi Mills(Beth Israel Deaconess Medical Center), Stefanie O'Brien(Beth Israel Deaconess Medical Center), Jeffrey I. Zwicker(Memorial Sloan Kettering Cancer Center), J Levine, Donna Fitzgerald(Beth Israel Deaconess Medical Center)

Transplantation and Cellular Therapy

January 10, 2012

Cited by 0

|Nature Immunology|2001|3k

|New England Journal of Medicine|2019|1.7k

|The Lancet|2021|1.7k

|New England Journal of Medicine|2018|1.4k

|New England Journal of Medicine|2016|1.4k

Related Papers